Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries
Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context.